Last reviewed · How we verify
Linezolid Injectable Product
Linezolid inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit, preventing peptide bond formation.
Linezolid inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit, preventing peptide bond formation. Used for Methicillin-resistant Staphylococcus aureus (MRSA) infections, Vancomycin-resistant Enterococcus (VRE) infections, Gram-positive bacterial infections including pneumonia and skin infections.
At a glance
| Generic name | Linezolid Injectable Product |
|---|---|
| Sponsor | Fundacion Clinic per a la Recerca Biomédica |
| Drug class | Oxazolidinone antibiotic |
| Target | Bacterial 50S ribosomal subunit (23S rRNA) |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | FDA-approved |
Mechanism of action
Linezolid is an oxazolidinone antibiotic that binds to the bacterial 23S rRNA component of the 50S ribosomal subunit, blocking the initiation of protein synthesis. This mechanism is bacteriostatic against most organisms but can be bactericidal against certain pathogens. It is effective against gram-positive bacteria, including methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant enterococci (VRE).
Approved indications
- Methicillin-resistant Staphylococcus aureus (MRSA) infections
- Vancomycin-resistant Enterococcus (VRE) infections
- Gram-positive bacterial infections including pneumonia and skin infections
Common side effects
- Thrombocytopenia
- Anemia
- Nausea
- Diarrhea
- Headache
- Peripheral neuropathy
- Optic neuropathy
Key clinical trials
- Testing a Novel Combination Treatment (Arm D) Versus Standard of Care for Intensive Phase Treatment for Mycobacterium Abscessus Pulmonary Disease in People With or Without Cystic Fibrosis in the Finding the Optimal Regimen for Mycobacterium Abscessus Treatment (FORMaT) Adaptive Platform Trial (PHASE2)
- Oral Antimicrobial Treatment vs. Outpatient Parenteral for Infective Endocarditis (PHASE4)
- Pharmacokinetic Study of Antiretroviral Drugs and Related Drugs During and After Pregnancy
- Bacteriophage Therapy for Mycobacterium Abscessus Pulmonary Infection (PHASE1)
- Pharmacokinetic Properties of Antiretroviral and Anti-Tuberculosis Drugs During Pregnancy and Postpartum
- Comparing Oral Versus Parenteral Antimicrobial Therapy (PHASE4)
- Randomized Controlled Multi-center Short Course Treatment for Rifampicin Resistant Tuberculosis (NA)
- Efficacy and Tolerability of Delamanid, Linezolid, Pyrazinamide and Levofloxacin (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: